This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MPP (Medicines Patent Pool) | |
|---|---|
| Name | MPP (Medicines Patent Pool) |
| Formation | 2010 |
| Type | Non-profit organization |
| Headquarters | Geneva, Switzerland |
| Leader title | Executive Director |
MPP (Medicines Patent Pool) is an international public health organization that negotiates voluntary licensing of patents for medicines to increase access in low- and middle-income countries. It operates within the context of global health initiatives and intellectual property frameworks to enable generic production and distribution of essential treatments across diverse markets.
The organization facilitates voluntary licensing agreements between patent holders and generic manufacturers to expand access to treatments for HIV/AIDS, hepatitis C, tuberculosis, and other diseases, engaging with stakeholders such as World Health Organization, UNAIDS, UNITAID, Bill & Melinda Gates Foundation, and national regulatory agencies. Its model intersects with intellectual property institutions like the World Trade Organization, the Patent Cooperation Treaty, and national patent offices in countries such as India, Brazil, South Africa, and China, while coordinating with procurement entities including the Global Fund and UNICEF.
Founded in 2010 following advocacy from UNITAID and support from actors including Clinton Foundation, the organization emerged amid debates at the World Health Assembly and negotiations under the TRIPS Agreement at the World Trade Organization. Early efforts built on precedents set by initiatives like the Pediatric HIV Initiative and policy proposals from entities including Médecins Sans Frontières and the Access to Medicine Foundation, catalyzing partnerships with pharmaceutical companies such as Gilead Sciences, ViiV Healthcare, and F. Hoffmann-La Roche.
Governance comprises a board with representatives from UN agencies, civil society, and the pharmaceutical sector, interacting with institutions such as UNAIDS, WHO, World Bank, European Commission, and philanthropic donors like the Wellcome Trust. Funding sources have included contributions from UNITAID, bilateral donors, and foundations, alongside in-kind support from manufacturers and technical partners such as Clinton Health Access Initiative and Management Sciences for Health. The governance model is influenced by corporate law norms from jurisdictions including Switzerland, United Kingdom, and United States.
The licensing framework negotiates non-exclusive, time-limited voluntary licenses permitting generic firms, often based in India or South Korea, to manufacture patented medicines for supply to designated territories including many low-income country and middle-income country lists; it incorporates sublicensing, technology transfer, and quality assurance pathways aligned with standards from World Health Organization prequalification and the US Food and Drug Administration. Operational activities span patent landscape analyses referencing databases like the European Patent Office, legal negotiations with originators including Gilead Sciences, AbbVie, and Bristol-Myers Squibb, and capacity-building with manufacturers such as Cipla, Hetero Drugs, and Mylan. The model leverages mechanisms from international agreements like the Paris Convention and interacts with regulatory reliance practices in regions such as Africa and Latin America.
Outcomes cited include expanded availability of generic antiretrovirals and direct-acting antivirals in dozens of countries, price reductions documented by procurement agencies including the Global Fund, increased manufacturing capacity among firms in India and Egypt, and integration into treatment guidelines by WHO and national ministries of health in countries like South Africa and Brazil. The organization reports sublicenses with multiple generic manufacturers and contributes to scale-up efforts for programs funded by entities like PEPFAR and UNITAID while influencing debates at forums including the World Health Assembly and the UN General Assembly.
Critiques have arisen from civil society groups such as Médecins Sans Frontières and commentators in journals like The Lancet over the pace of licensing, geographic scope of territories, and exclusions for upper-middle-income countries, engaging policy debates involving TRIPS flexibilities, compulsory licensing episodes in countries like Thailand and India, and strategic behavior by originator firms including Gilead Sciences and GlaxoSmithKline. Other controversies involve tension between voluntary mechanisms and proposals for more expansive measures by multilateral actors including WHO and advocates at the UN High-Level Meeting on Universal Health Coverage.
The organization partners with a broad network including UNITAID, WHO, UNAIDS, Global Fund, bilateral agencies such as USAID, philanthropic organizations like the Bill & Melinda Gates Foundation, civil society groups including Médecins Sans Frontières and Treatment Action Campaign, and manufacturers ranging from Cipla to multinational firms such as Gilead Sciences and ViiV Healthcare. Collaborative efforts extend to academic institutions like Harvard University and London School of Hygiene & Tropical Medicine for research, and policy engagement at international venues including the World Health Assembly and meetings of the World Trade Organization.
Category:Public health organizations Category:Intellectual property law